Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19.

Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19. Hum Vaccin Immunother. 2020 06 02; 16(6):1239-1242.

View in: PubMed

subject areas

Betacoronavirus
Coronavirus Infections
Humans
Pandemics
Pneumonia, Viral
Protein Domains
Protein Subunits
Recombinant Proteins
Viral Envelope Proteins
Viral Vaccines

authors with profiles

MARIA BOTTAZZI
PETER HOTEZ
WEN-HSIANG CHEN